JERUSALEM, November 1, 2012 /PRNewswire/ --
SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of patent-pending voice recognition technology that reduces the risks of errors during the administration of prescription medications, announced today that shares of SafeCode Drug Technologies common stock have commenced trading on the OTC Bulletin Board under the symbol "SAFC".
Trading began shortly after the company was granted eligibility status by the Depository Trust Company (DTC).
SafeCode is the developer of the world's first patent-pending voice recognition technology used to confirm prescription medications prior to their administration at home or in a medical center.
Using SafeCode technology, prescription medications stored in specially designed locked containers can only be accessed and administered once the caregiver or patient correctly announces the name of the drug.
The technology ensures that the appropriate medication is being administered, as mistakes have accounted for thousands of deaths in recent years. Often, nurses, doctors or patients are not careful when giving or taking medications, and many medication's packaging may look similar. SafeCode Technology prevents medication errors, and thereby reduces the risk of severe injury or accidental death.
"We are certain that the wider investment community will recognize the commercial potential for SafeCode Drug Technologies," said Joel Klopfer , Chief Executive Officer of SafeCode Drug Technologies. "We are excited to bring this potentially life-saving technology to market, and will keep our investors abreast of the company's development in the coming weeks and months."
About SafeCode Drug Technologies
SafeCode Drug Technologies is the developer of a patent-pending voice recognition technology that provides an essential degree of security that can effectively prevent unauthorized administration of a prescription medication.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact:
CFO, Joel Klopfer
Joel.klopfer1@gmail.com
+972-25021321
SOURCE Safecode Drug Technologies Corp.
